Home›Stock Screener›Concord Biotech›Quarterly Results

Concord Biotech Quarterly Results

Latest Quarter Net Profit
₹89 Cr
QMar 2026
Quarterly Results

Concord Biotech quarterly results. In Mar 2026, Concord Biotech (CONCORDBIO) reported revenue ₹341 Cr and net profit ₹89 Cr — revenue -22.3% YoY. Review CONCORDBIO price earnings ratio to evaluate earnings-based valuation against sector peers.

CONCORDBIO Quarterly Results — Revenue, Profit & EPS Highlights

Concord Biotech latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Check CONCORDBIO market cap trends to track the company's total market size over time.

  • Revenue of ₹341 Cr in Mar 2026 (+25.4% vs Jun 2026, -22.3% vs Mar 2025)
  • Net Profit of ₹89 Cr in Mar 2026 (+53.4% vs Jun 2026, -36.4% vs Mar 2025)
  • EBITDA of ₹134 Cr in Mar 2026 (+38.1% vs Jun 2026)
  • Operating Margin of 36.0% in Mar 2026 (+4.0pp vs Jun 2026)
  • Earnings Per Share of ₹8.46 in Mar 2026 (+53.3% vs Jun 2026)

Concord Biotech Quarterly Results — Revenue, EBITDA, Net Profit & EPS

CONCORDBIO quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Mar 2026 Jun 2026 Sept 2025 Mar 2025 Jun 2025 QoQ YoY
Revenue (₹ Cr) 341 272 263 439 219 25.4% -22.3%
Net Profit (₹ Cr) 89 58 63 140 44 - -
EBITDA (₹ Cr) 134 97 104 198 77 - -
EPS (₹) 8.46 5.52 6.03 13.42 4.21 - -
Operating Margin (%) 36.0% 32.0% 36.0% 44.0% 30.0% - -

CONCORDBIO Share Price Trend — 1-Year Movement Across Quarterly Results

Concord Biotech 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Concord Biotech share price chart.

Profitability Ratios

Profit Margin 26.1%
EBITDA Margin 39.3%
Operating Margin 36.0%
ROE (Annual) 17.7%

Balance Sheet Highlights

Total Assets ₹2,235 Cr
Total Equity ₹2,015 Cr
Current Assets ₹ Cr
Current Liabilities ₹51 Cr

Cash Flow Analysis

Operating Cash Flow ₹267 Cr
Investing Cash Flow ₹-143 Cr
Financing Cash Flow ₹-113 Cr
Net Cash Flow ₹11 Cr

Current Market Data

Current Price ₹1270.70
Exchange NSE
Last Updated Oct 22, 2026

Revenue Trend (₹ Cr)

Mar 2025 439
Sept 2025 263
Jun 2026 272
Mar 2026 341

Net Profit Trend (₹ Cr)

Mar 2025 140
Sept 2025 63
Jun 2026 58
Mar 2026 89

Operating Margin Trend (%)

Mar 2025 44.0%
Sept 2025 36.0%
Jun 2026 32.0%
Mar 2026 36.0%

CONCORDBIO vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Concord Biotech latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Mar 2026 		₹421,995.00 Cr 1758.0 15,018 2,710 -5.6% - 18.0% 155.6
Divis Laboratories
Mar 2026 		₹241,231.30 Cr 9162.0 2,986 751 -5.0% - 25.2% 323.6
Torrent Pharmaceuti…
Mar 2026 		₹188,719.51 Cr 4615.3 4,111 364 +27.7% +42.2% 8.9% 401.0
Laurus Labs
Mar 2026 		₹111,790.60 Cr 2002.5 1,823 282 -10.5% - 15.5% 387.3
Zydus Life Science
Mar 2026 		₹111,111.95 Cr 1135.0 7,569 1,341 -4.3% - 17.7% 89.7
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data

QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores